Laura Bukavina: Age doesn’t limit EV efficacy
Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a recent recent article by Tetsuya Shindo on X:
“Age doesn’t limit EV efficacy.
Older patients (≥75) saw an ORR of 60%, with median progression-free survival at 223 days and OS at 407 days—comparable to younger patients. Percentage of liver dysfunction (0% vs. 24%).”
Authors: Tetsuya Shindo, Kohei Hashimoto, Toshiki Kenuka, Shintaro Miyamoto, Yoshiki Hiyama, Fumimasa Fukuta, Yasuharu Kunishima, Manabu Okada, Masanori Matsukawa, Ryuichi Kato, Masaya Senda, Atsushi Wanifuchi, Shunsuke Sato, Ko Kobayashi, Toshiaki Tanaka and Naoya Masumori
Niklas Klümper, Senior Urology Consultant at the University Medical Center Bonn, also shared an article on X:
“Thanks for sharing Laura Bukavina.
That’s exciting because we have demonstrated that NECTIN4 amplification, which is strongly predictive for EV response, seems to occur more frequently in elderly patients, which might be part of the explanation of the 60% ORR.”
Authors: Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E. Vera Badillo, J. Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel and Markus Eckstein
Niklas Klümper, MD, is a senior urology consultant specializing in genitourinary (GU) oncology and an advanced clinician-scientist at the University Medical Center Bonn (UKB), supported by the BMBF-funded ACCENT program. He leads a translational uro-oncology research group that bridges the Department of Urology and the Institute of Experimental Oncology. His research focuses on improving treatment response predictions for targeted therapies, developing personalized treatment strategies, and conducting clinical trials to enhance outcomes for patients with uro-oncological diseases.
More posts featuring Laura Bukavina and Niklas Klümper.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023